Aclarion, Inc. (ACON)
After hours:
| Previous Close | 0.3060 |
| Open | 0.3195 |
| Bid | 0.2240 x 200 |
| Ask | 0.3968 x 200 |
| Day's Range | 0.3030 - 0.3290 |
| 52 Week Range | 0.2670 - 11.5040 |
| Volume | |
| Avg. Volume | 590,960 |
| Market Cap | 2.657M |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.4700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- GlobeNewswire
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care Market BROOMFIELD, CO, July 09, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain,
- GlobeNewswire
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First Insurance Company to Approve Payment for Nociscan BROOMFIELD, CO, June 26, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify
- GlobeNewswire
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging
